McKitty v. Advanced Tissue Sciences, Inc.

184 F.R.D. 346, 1998 U.S. Dist. LEXIS 16926, 1998 WL 961283
CourtDistrict Court, S.D. California
DecidedOctober 20, 1998
DocketNo. 98-1146-IEG(LAB)
StatusPublished
Cited by33 cases

This text of 184 F.R.D. 346 (McKitty v. Advanced Tissue Sciences, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
McKitty v. Advanced Tissue Sciences, Inc., 184 F.R.D. 346, 1998 U.S. Dist. LEXIS 16926, 1998 WL 961283 (S.D. Cal. 1998).

Opinion

[347]*347ORDER DENYING ARYEH GROUP’S (PRINCIPAL) MOTION FOR APPOINTMENT AS LEAD PLAINTIFF; DENYING ARYEH GROUP’S (ALTERNATE) MOTION FOR CREATION OF CO-LEAD PLAINTIFF/CO-LEAD COUNSEL STRUCTURE; DENYING ARYEH GROUP’S MOTION FOR APPROVAL OF LEAD COUNSEL; DENYING MCKITTY GROUP’S (PRINCIPAL) MOTION FOR APPOINTMENT AS LEAD PLAINTIFF; GRANTING MCKITTY GROUP’S (ALTERNATE) MOTION FOR APPOINTMENT OF SIX LEAD PLAINTIFFS; GRANTING MCKITTY GROUP’S MOTION FOR APPROVAL OF LEAD COUNSEL

GONZALEZ, District Judge.

This is a securities fraud action brought pursuant to the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 (“PSLRA”). Now before the Court are two competing motions for appointment as lead plaintiff and for approval of lead counsel, one from the Aryeh Plaintiffs Group (“Aryeh Group”) and the other from the McKitty Plaintiffs Group (“McKitty Group”).

BACKGROUND

The instant motions arise from a total of seven putative class actions, each of which alleges violations of federal securities laws by Advanced Tissue Sciences, Inc., (“ATS”) and certain of its officers and directors.1 The complaints are brought pursuant to the Securities and Exchange Act, as well as Rule 10-b5 promulgated thereunder. Plaintiffs commonly allege that defendants issued false and misleading statements regarding the testing, and potential for FDA approval, of Dermagraft, a new product that ATS is seeking to market for the treatment of diabetic foot ulcers. Plaintiffs further allege that, in reliance upon defendants’ alleged misstatements — in particular, defendants’ representations about early clinical trial results of Dermagraft and its likelihood for FDA approval — plaintiffs purchased ATS stock at artificially inflated prices. Plaintiffs claim that they suffered, collectively, millions of dollars in damages when ATS’s stock lost much of its value following a determination by the FDA that the data from ATS’s clinical trials was insufficient to warrant approval of Dermagraft.

On June 22, 1998, the McKitty Group filed the first of the above-referenced actions against defendants. The McKitty Group consists of over 250 unrelated, individual investors who purchased approximately 720,-000 shares of ATS stock between October 14, 1996, and June 11, 1998 (the proposed class period).2 The McKitty Group claims to have [348]*348suffered an aggregate pecuniary loss of $4,508,950.3

On June 30, 1998, the Aryeh Group filed its action against defendants. The Aryeh Group consists of approximately 165 unrelated, individual investors who purchased roughly 400,000 shares of ATS stock during the proposed class period.4 The Aryeh Group claims to have suffered an aggregate pecuniary loss of $3,096,682.02.5

On August 21, 1998, both the McKitty Group and Aryeh Group filed their present motions. The McKitty Group moves this Court for: (1) the appointment of the McKitty Group as lead plaintiff, or in the alternative, the appointment of six designated shareholders from the McKitty Group as lead plaintiffs,6 and (2) approval of its selection of counsel. Similarly, the Aryeh Group moves this Court for: (1) the appointment of the Aryeh Group as lead plaintiff, and (2) approval of its selection of counsel.7 Both parties have submitted opposition and reply briefs in support of their motions. On September 29, 1998, defendants filed a response.8 No other plaintiff, or group of plaintiffs, has filed a motion seeking appointment as lead plaintiff.

DISCUSSION

A. Motion For Appointment As Lead Plaintiff

1. Standard óf Review

The motions now before the Court are governed by section 21 of the PSLRA The PSLRA states that within twenty days after the date on which a class action is filed under the PSLRA:

the plaintiff or plaintiffs shall cause to be published, in a widely circulated national business-oriented publication or wire service, a notice advising members of the purported plaintiff class — (I) of the pendency of the action, the claims asserted therein, and the purported class period; and (II) that, no later than 60 days after the date on which the notice is published, any member of the purported class may move the court to serve as lead plaintiff of the purported class.

15 U.S.C. § 78u-4(a)(3)(A)(i). When there is more than one putative class asserting substantially the same claim under the PSLRA, [349]*349a court should first consolidate the actions, see id. § 78u-4(a)(3)(B)(ii), and as soon as practicable thereafter, appoint as lead plaintiff, “the member or members of the purported plaintiff class that the court determines to be most capable of adequately representing the interests of class members.” Id. § 78u-4(a)(3)(B)®.

In selecting the group of class members who are the most capable of adequately representing the class — i.e., the most adequate plaintiff — the PSLRA directs:

the court shall adopt a presumption that the most adequate plaintiff ... is the person or group of persons that — (aa) has either filed the complaint or made a motion in response to a notice under subparagraph (A)(i); (bb) in the determination of the court, has the largest financial interest in the relief sought by the class; and (ce) otherwise satisfies the requirements of Rule 23 of the Federal Rules of Civil Procedure.

Id. § 78u-4(a)(3)(B)(iii)(I).9 This presumption “may be rebutted only upon proof ... that the presumptively most adequate plaintiff — (aa) will not fairly and adequately protect the interests of the class; or (bb) is subject to unique defenses that render such plaintiff incapable of adequately representing the class.” Id. § 78u-4(a)(3)(B)(iii)(II).

2. Legal Analysis

Having laid out the statutory standard for the appointment of lead plaintiff, the Court now turns to the parties’ motions.

a. Analysis of Presumption’s Requirements

i. Notice

Both the McKitty Group and Aryeh Group satisfy the first requirement of § 78u-4(a)(3)(B)(iii)(I). The McKitty Group published and disseminated the required statutory notice over the Business Wire on July 23, 1998, the day after the filing of McKitty’s complaint. The Aryeh Group filed its motion for appointment as lead plaintiff within sixty days of the publication of the McKitty Group’s notice, on August 21, 1998. Neither group disputes that the other group has satisfied the statutory notice requirement.

ii. Elements of Class Action

As for the third requirement, a wide-ranging analysis of whether the McKitty Group and Aryeh Group meet the requirements for class action certification is not required at this stage. For the purposes of a motion for appointment as lead plaintiff, a proposed lead plaintiff must only make a preliminary showing that he or she satisfies the requirements of Rule 23(a). See, e.g., Gluck v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Subramanian v. Watford
D. Colorado, 2021
Bussom v. Watford
D. Colorado, 2021
Barnet v. Elan Corp.
236 F.R.D. 158 (S.D. New York, 2005)
Tanne v. Autobytel, Inc.
226 F.R.D. 659 (C.D. California, 2005)
In re Cardinal Health, Inc.
226 F.R.D. 298 (S.D. Ohio, 2005)
Ferrari v. Gisch
225 F.R.D. 599 (C.D. California, 2004)
Lehocky v. Tidel Technologies, Inc.
220 F.R.D. 491 (S.D. Texas, 2004)
Meyer v. Paradigm Medical Industries
225 F.R.D. 678 (D. Utah, 2004)
Newman v. Eagle Building Technologies
209 F.R.D. 499 (S.D. Florida, 2002)
Newby v. Enron Corp.
206 F.R.D. 427 (S.D. Texas, 2002)
In Re: Cendant Corp.
Third Circuit, 2001
Martin v. Atchison Casting Corp.
200 F.R.D. 453 (D. Kansas, 2001)
Weltz v. Lee
199 F.R.D. 129 (S.D. New York, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
184 F.R.D. 346, 1998 U.S. Dist. LEXIS 16926, 1998 WL 961283, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mckitty-v-advanced-tissue-sciences-inc-casd-1998.